+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Hyperhidrosis Treatment Market by Treatment Type, Distribution Channel, Anatomical Site, Condition Type, Treatment Setting - Global Forecast to 2030- Product Image
Hyperhidrosis Treatment Market by Treatment Type, Distribution Channel, Anatomical Site, Condition Type, Treatment Setting - Global Forecast to 2030- Product Image
Sale

Hyperhidrosis Treatment Market by Treatment Type, Distribution Channel, Anatomical Site, Condition Type, Treatment Setting - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715634
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hyperhidrosis Treatment Market grew from USD 647.88 million in 2024 to USD 694.14 million in 2025. It is expected to continue growing at a CAGR of 7.01%, reaching USD 973.01 million by 2030.

Unveiling the Dynamics of the Hyperhidrosis Treatment Market

Despite its often private nature, hyperhidrosis affects millions worldwide and poses significant clinical and social challenges. Characterized by excessive sweating beyond physiological needs, the condition can lead to discomfort, embarrassment, and secondary complications such as skin infections and psychological distress. Recent advances in diagnostic criteria and patient education have catalyzed demand for effective, targeted treatments that improve daily functioning and overall well-being. Meanwhile, the interplay between patient advocacy groups, regulatory agencies, and industry innovators has shaped a complex environment where speed to market and evidence generation are critical. This report explores the multifaceted hyperhidrosis treatment market by unpacking core drivers, examining therapeutic modalities, and illuminating strategic considerations that will guide industry participants through the next decade.

As treatment preferences shift toward minimally invasive approaches, stakeholder collaboration across clinical, commercial, and technological domains becomes indispensable. Understanding these dynamics is essential for health care providers evaluating new offerings, for manufacturers optimizing product pipelines, and for payers balancing efficacy with cost containment. By contextualizing the current landscape, this executive summary lays the groundwork for deeper insights into transformative trends, tariff impacts, segmentation analysis, regional variations, and actionable recommendations for market leadership.

Emerging Drivers Redefining Treatment Opportunities

The hyperhidrosis market is undergoing a paradigm shift driven by patient-centric innovation and technological convergence. Clinicians and developers are embracing combination therapies that integrate pharmacological agents with device-based approaches, yielding synergistic efficacy and expanded patient choice. Advancements in iontophoresis and microwave thermolysis technologies have transformed at-home care modalities, empowering individuals to manage symptoms discreetly and effectively. At the same time, breakthroughs in peptide-based topical formulations and next-generation botulinum toxins are poised to extend therapeutic windows and reduce dosing frequency.

Regulatory bodies are also adapting, streamlining pathways for device approvals and fostering harmonization across major markets. Digital health platforms and telemedicine integration have emerged as critical enablers for remote diagnostics, virtual consultations, and adherence monitoring. Meanwhile, insurers are reassessing reimbursement frameworks to accommodate innovative treatments that promise long-term cost savings by mitigating complications and enhancing patient outcomes. Together, these forces are redefining the competitive landscape, accelerating product development cycles, and elevating the standard of care in hyperhidrosis management.

Assessing the 2025 US Tariff Effects on Supply and Pricing

The implementation of new US tariffs in 2025 has exerted a significant influence on the hyperhidrosis supply chain and pricing strategies. Import duties applied to medical devices such as iontophoresis units and microwave thermolysis platforms have increased manufacturing and distribution costs, prompting many suppliers to reevaluate production locations and source alternative materials. Concurrently, tariffs on active pharmaceutical ingredients have affected the cost structure of injectable therapies, including botulinum toxin derivatives, and topical agents formulated with aluminum chloride or glycopyrronium.

These cost pressures have been partially absorbed through minor price adjustments in clinical settings, while manufacturers have intensified negotiations with logistics partners to offset freight surcharges. Some global players have accelerated plans to localize assembly or contract production in tariff-exempt regions, mitigating the impact on end users. Insurers and health care systems are monitoring reimbursement policies closely, seeking to ensure that out-of-pocket expenses remain manageable for patients. As a result, strategic realignment across procurement, manufacturing, and distribution channels has become an imperative for stakeholders aiming to preserve market share and maintain competitive pricing.

Holistic Segmentation Reveals Targeted Market Niches

A nuanced segmentation framework reveals the heterogeneity of demand and growth opportunities across treatment modalities, channels, anatomical presentations, condition types, and care settings. Within treatment type, injectable therapies anchored by Botulinum Toxin Type A maintain a leading role due to extensive clinical validation and robust provider familiarity, while Type B formulations offer alternative mechanisms for patients with resistant cases. Medical devices have diversified the landscape, with iontophoresis devices appealing to at-home users seeking noninvasive regimens, and microwave thermolysis platforms gaining traction in specialized clinics for longer-lasting results. Oral medications such as anticholinergics provide systemic relief for multifocal hyperhidrosis, whereas beta blockers serve niche indications for situational sweating. Topical agents including aluminum chloride hexahydrate remain first-line underarm treatments, while glycopyrronium tosylate introduces targeted anticholinergic effects with reduced systemic exposure.

Distribution channels underscore the balance between accessibility and clinical oversight. E-commerce portals have expanded patient reach and discreet procurement, complementing traditional over-the-counter venues in online and brick-and-mortar pharmacies. Prescription pathways through dermatology clinics and hospital settings facilitate the integration of advanced devices and combination protocols under professional supervision. Anatomical segmentation highlights underarm presentations as the largest cohort due to both prevalence and visibility concerns, with palmar, plantar, and facial hyperhidrosis representing specialized therapeutic niches. Differentiation between primary idiopathic cases and secondary hyperhidrosis tied to metabolic or neurological conditions shapes product positioning and treatment algorithms. Care settings range from home-based regimens enabled by user-friendly devices to clinic-based services provided in general and specialized practices, with inpatient and outpatient hospital programs reserved for surgical procedures and high-acuity interventions.

Regional Variations Highlight Strategic Growth Zones

Regional dynamics paint a complex tapestry of demand drivers and adoption patterns. In the Americas, robust reimbursement schemes and established channels for botulinum toxin therapies continue to fuel growth, bolstered by high patient awareness and clinician familiarity with device-based platforms. Shifting to Europe, Middle East & Africa, regulatory harmonization across the European Union has accelerated approvals for novel devices, while Middle Eastern markets demonstrate a willingness to invest in advanced therapeutics that address quality of life concerns. Variability in reimbursement policies, however, necessitates tailored market access strategies.

Across Asia-Pacific, markets such as China and Japan exhibit rapid uptake of both pharmacological and device innovations, driven by growing affluence and expanding hospital infrastructure. Meanwhile, emerging markets in Southeast Asia and India are characterized by price sensitivity and a preference for cost-effective generics and OTC offerings. Each region presents unique barriers and enablers, from regulatory timelines to cultural stigmas, underscoring the importance of localized insights and adaptive commercial frameworks.

Competitive Landscape Illuminates Innovation Pathways

Leading organizations are leveraging diverse strategies to capture value in the hyperhidrosis space. Established pharmaceutical companies draw on long-standing botulinum toxin franchises, investing in next-generation formulations and expanding label indications. Dermatology-focused innovators are accelerating pipelines with peptide-based topicals and novel delivery mechanisms. Device manufacturers are forging partnerships with technology firms to integrate smart sensors, connectivity features, and data analytics into at-home platforms.

Smaller enterprises are disrupting traditional models by emphasizing patient convenience and subscription-based services, while strategic alliances and mergers and acquisitions have created synergistic portfolios that span pharmacological, surgical, and device-based treatments. Across the competitive landscape, agility in clinical development, regulatory engagement, and reimbursement negotiations emerges as a defining differentiator for companies seeking to achieve sustainable growth.

Strategic Imperatives for Leaders Eyeing Market Advantage

Industry leaders should prioritize investment in integrated R&D programs that bridge pharmacological and device technologies, unlocking combination approaches with superior efficacy and patient adherence. Strengthening supply chain resilience through diversified manufacturing footprints and tariff-aware sourcing will mitigate cost volatility and ensure timely product availability. Cultivating partnerships with telehealth platforms and digital health startups can extend reach into underserved populations while enhancing patient engagement and adherence through remote monitoring tools.

Market access strategies should emphasize value-based contracting and real-world evidence generation, demonstrating long-term cost savings to payers and health systems. Educational initiatives targeting both medical professionals and end users can elevate disease awareness and reduce stigma, fostering earlier intervention. Finally, tailoring commercial models to regional nuances-from high-end clinical programs in developed markets to cost-effective OTC solutions in price-sensitive territories-will optimize revenue potential and support global expansion efforts.

Methodical Framework Underpinning Robust Market Insights

This analysis draws upon a rigorous methodology combining primary and secondary research. Primary insights were gathered through interviews with key opinion leaders including dermatologists, neurologists, endocrine specialists, and hospital administrators across major markets. These conversations provided qualitative perspectives on clinical practice patterns, therapeutic preferences, and adoption barriers.

Secondary research encompassed a comprehensive review of peer-reviewed journals, regulatory filings, patent databases, corporate reports, and industry white papers. Data triangulation techniques ensured cross-validation of information, while a structured segmentation framework enabled granular dissecting of treatment types, distribution channels, anatomical sites, condition categories, and care settings. The resulting intelligence offers robust, unbiased insights without reliance on proprietary forecasting models, equipping stakeholders with actionable knowledge grounded in empirical evidence.

Synthesizing Key Takeaways to Guide Future Initiatives

The hyperhidrosis treatment landscape is defined by accelerating innovation, evolving regulatory paradigms, and shifting patient expectations. From injectable therapies anchored by established botulinum toxins to emerging home-based devices and advanced topicals, a diverse array of options addresses distinct clinical presentations and care settings. Regional disparities in reimbursement, cultural attitudes, and regulatory timelines underscore the necessity for tailored market access and commercial strategies.

As tariff impacts reshape supply chains and pricing considerations, companies that proactively adapt sourcing, manufacturing, and distribution plans will safeguard margins while maintaining patient affordability. Strategic collaboration across pharmacological, device, and digital health domains will unlock new combination therapies and enhance adherence. By leveraging the insights presented in this report, stakeholders can identify high-potential segments, engage with target audiences effectively, and position their organizations for sustained leadership in the dynamic hyperhidrosis treatment market.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Injectable Treatments
      • Botulinum Toxin Type A
      • Botulinum Toxin Type B
    • Medical Devices
      • Iontophoresis Devices
      • Microwave Thermolysis Devices
    • Oral Medications
      • Anticholinergics
      • Beta Blockers
    • Surgical Treatments
    • Topical Agents
      • Aluminum Chloride Hexahydrate
      • Glycopyrronium Tosylate
  • Distribution Channel
    • E Commerce
    • OTC
      • Online Pharmacies
      • Retail Pharmacies
    • Prescription
      • Dermatology Clinics
      • Hospitals
  • Anatomical Site
    • Face
    • Feet
    • Palms
    • Underarm
  • Condition Type
    • Primary Hyperhidrosis
    • Secondary Hyperhidrosis
  • Treatment Setting
    • Clinic
      • General Clinics
      • Specialized Clinics
    • Home
    • Hospital
      • Inpatient
      • Outpatient
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Ipsen S.A.
  • Galderma S.A.
  • Merz Pharma GmbH & Co. KGaA
  • Hologic, Inc.
  • Eli Lilly and Company
  • Evolus, Inc.
  • Revance Therapeutics, Inc.
  • Dermira, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Hyperhidrosis Treatment Market, by Treatment Type
8.1. Introduction
8.2. Injectable Treatments
8.2.1. Botulinum Toxin Type a
8.2.2. Botulinum Toxin Type B
8.3. Medical Devices
8.3.1. Iontophoresis Devices
8.3.2. Microwave Thermolysis Devices
8.4. Oral Medications
8.4.1. Anticholinergics
8.4.2. Beta Blockers
8.5. Surgical Treatments
8.6. Topical Agents
8.6.1. Aluminum Chloride Hexahydrate
8.6.2. Glycopyrronium Tosylate
9. Hyperhidrosis Treatment Market, by Distribution Channel
9.1. Introduction
9.2. E Commerce
9.3. OTC
9.3.1. Online Pharmacies
9.3.2. Retail Pharmacies
9.4. Prescription
9.4.1. Dermatology Clinics
9.4.2. Hospitals
10. Hyperhidrosis Treatment Market, by Anatomical Site
10.1. Introduction
10.2. Face
10.3. Feet
10.4. Palms
10.5. Underarm
11. Hyperhidrosis Treatment Market, by Condition Type
11.1. Introduction
11.2. Primary Hyperhidrosis
11.3. Secondary Hyperhidrosis
12. Hyperhidrosis Treatment Market, by Treatment Setting
12.1. Introduction
12.2. Clinic
12.2.1. General Clinics
12.2.2. Specialized Clinics
12.3. Home
12.4. Hospital
12.4.1. Inpatient
12.4.2. Outpatient
13. Americas Hyperhidrosis Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Hyperhidrosis Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Hyperhidrosis Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Bausch Health Companies Inc.
16.3.3. Ipsen S.A.
16.3.4. Galderma S.A.
16.3.5. Merz Pharma GmbH & Co. KGaA
16.3.6. Hologic, Inc.
16.3.7. Eli Lilly and Company
16.3.8. Evolus, Inc.
16.3.9. Revance Therapeutics, Inc.
16.3.10. Dermira, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. HYPERHIDROSIS TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. HYPERHIDROSIS TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. HYPERHIDROSIS TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. HYPERHIDROSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. HYPERHIDROSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. HYPERHIDROSIS TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY BOTULINUM TOXIN TYPE A, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY BOTULINUM TOXIN TYPE B, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY IONTOPHORESIS DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY MICROWAVE THERMOLYSIS DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ALUMINUM CHLORIDE HEXAHYDRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY GLYCOPYRRONIUM TOSYLATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY FACE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY FEET, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY PALMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY UNDERARM, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRIMARY HYPERHIDROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY SECONDARY HYPERHIDROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 80. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 82. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 83. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 84. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 85. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 87. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 88. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 89. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 90. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 91. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 92. CANADA HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 93. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 96. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 100. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 101. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 102. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 104. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 105. MEXICO HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 159. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 160. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 161. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 162. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 163. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 164. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 166. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 167. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 168. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 169. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 170. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 171. GERMANY HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 172. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 174. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 175. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 179. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 180. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 181. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 182. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 183. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 184. FRANCE HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 198. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 199. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 200. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 201. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 202. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 203. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 205. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 206. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 207. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 208. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 209. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 210. ITALY HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 211. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 212. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 213. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 214. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 215. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 216. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 218. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 219. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 220. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 221. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 222. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 223. SPAIN HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 263. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 265. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 266. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 267. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 268. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 270. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 271. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 272. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 273. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 274. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 275. DENMARK HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 276. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 277. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 278. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 279. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 280. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 281. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 289. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 290. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 291. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 292. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 293. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 294. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 296. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 297. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 298. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 299. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 300. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 301. QATAR HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 302. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 303. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 304. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 305. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 306. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 307. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 309. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 310. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 311. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 312. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2030 (USD MILLION)
TABLE 313. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY CLINIC, 2018-2030 (USD MILLION)
TABLE 314. FINLAND HYPERHIDROSIS TREATMENT MARKET SIZE, BY HOSPITAL, 2018-2030 (USD MILLION)
TABLE 315. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 316. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY INJECTABLE TREATMENTS, 2018-2030 (USD MILLION)
TABLE 317. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
TABLE 318. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2030 (USD MILLION)
TABLE 319. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY TOPICAL AGENTS, 2018-2030 (USD MILLION)
TABLE 320. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY OTC, 2018-2030 (USD MILLION)
TABLE 322. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
TABLE 323. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY ANATOMICAL SITE, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN HYPERHIDROSIS TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN HYPERHIDROSI

Companies Mentioned

The companies profiled in this Hyperhidrosis Treatment market report include:
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Ipsen S.A.
  • Galderma S.A.
  • Merz Pharma GmbH & Co. KGaA
  • Hologic, Inc.
  • Eli Lilly and Company
  • Evolus, Inc.
  • Revance Therapeutics, Inc.
  • Dermira, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 694.14 Million
Forecasted Market Value ( USD ) by 2030 $ 973.01 Million
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Hyperhidrosis Treatment Market Report 2025 - Product Image

Hyperhidrosis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Hyperhidrosis Treatment - Global Strategic Business Report - Product Image

Hyperhidrosis Treatment - Global Strategic Business Report

  • Report
  • 480 Pages
  • Global
From
Hyperhidrosis - Pipeline Insight, 2025 - Product Image

Hyperhidrosis - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Axillary Hyperhidrosis - Pipeline Insight, 2025 - Product Image

Axillary Hyperhidrosis - Pipeline Insight, 2025

  • Drug Pipelines
  • 40 Pages
  • Global
From
Botulinum Toxins in Dermatology & Cosmetology Market by Product Type, Therapeutic Indication, End User, Distribution Channel, Route Of Administration - Global Forecast to 2030 - Product Image

Botulinum Toxins in Dermatology & Cosmetology Market by Product Type, Therapeutic Indication, End User, Distribution Channel, Route Of Administration - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From

About the Hyperhidrosis Drug Market

Hyperhidrosis is a medical condition characterized by excessive sweating. It is a common disorder that affects millions of people worldwide. Endocrinology is the branch of medicine that deals with the diagnosis and treatment of disorders related to hormones and the endocrine system. Hyperhidrosis is a disorder that is often treated by endocrinologists. The hyperhidrosis drug market is a rapidly growing segment of the endocrinology market. It is driven by the increasing prevalence of hyperhidrosis, the availability of new treatments, and the growing awareness of the condition. The market is expected to grow at a steady rate in the coming years due to the increasing demand for effective treatments. Some of the major companies in the hyperhidrosis drug market include GlaxoSmithKline, Merck & Co., Pfizer, Johnson & Johnson, and Novartis. These companies are actively involved in the development and marketing of drugs for the treatment of hyperhidrosis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.